Drug Trial Radar · NCT07948395
Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in Ethiopia
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 10, 2026
Primary completion
Apr 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- University of AarhusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Biological E. Limited; Debre Markos University
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Helminth infections affect over 1.5 billion people and weaken the response to vaccination. CORBEVAX contains the TLR9-activating adjuvant CpG 1018, which may overcome this. This trial measures the immunogenicity of CORBEVAX in adults with and without Schistosoma mansoni or hookworm infection in Ethiopia. The primary measure is spike-specific serum IgG at Day 42; antibody subclass, T-cell, neutralisation and regulatory T-cell responses are measured as secondary outcomes up to Day 90. This is the first of two planned cohorts under a shared protocol; a second cohort receiving an mRNA COVID-19 vaccine at the same sites is planned subject to vaccine availability and will be registered separately.
Conditions
- Schistosomiasis Mansoni
- Hookworm Infection
- COVID-19
Interventions
Biological: CORBEVAXBiological
Recombinant SARS-CoV-2 receptor-binding-domain protein subunit vaccine adjuvanted with CpG 1018 and alum (Biological E Limited). Two intramuscular doses(0.5 ml/dose), Day 0 and Day 28 (±3 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean concentration of serum anti-SARS-CoV-2 spike IgG, by helminth infection statusTime frame: Day 42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Andasa Health Centre
Bahir Dar, Amhara, Ethiopia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.